Aarti Pharmalabs Limited (AARTIPHARM) share price
₹826.95 on NSE as of 2026-09-11. +0.15% on the day. market cap ₹7,499 Cr. P/E 35.2. 52-week range ₹591.95 to ₹939.50. Healthcare.
Aarti Pharmalabs Q1 FY27: Revenue ₹536 Cr, Xanthine at a Record, and a ₹149 Crore Block Approved
At a glance
Consolidated revenue for the June 2026 quarter came in at ₹536 crore against ₹386 crore a year earlier, up 38.7%. Operating profit was ₹136 crore versus ₹93 crore, and net profit ₹76.1 crore against ₹49.5 crore. EPS moved from ₹5.46 to ₹8.40.
The quarter had things happening in it, which is not always true of a caffeine manufacturer's June. Management described Q1 as "the highest ever quarterly sales of Xanthine derivatives." The board, meeting on 7 August, approved the results, approved ₹149 crore of new capacity at Atali, and rearranged two of its most senior job titles — a four-hour meeting, per the filing, from 2 p.m. to 6 p.m., which for that agenda is brisk.
Xanthine derivatives contributed 57% of Q1 FY27 revenue, API and Intermediates 30%, CDMO/CMO 7%, and Others 6%. Management noted that Unit 4's Steroid API block sat through a six-week debottlenecking shutdown during the quarter, emerging with a third more capacity and a quarter's worth of lost output — the industrial equivalent of remodelling the kitchen in the week you host dinner.
The March 2026 quarter, for comparison, delivered ₹583 crore of revenue and ₹61.1 crore of profit. The June quarter's revenue was 8.0% lower and its profit 24.6% higher.
Introduction
Aarti Pharmalabs is the pharmaceutical half of a chemicals family that decided, in October 2022, to stop sharing a bank account. The company was incorporated in 2019 as a wholly owned subsidiary of Aarti Industries under the name Aarti Organics, and demerged into a separately listed entity — which is how a 25-year-old manufacturing operation ends up with a corporate birth certificate younger than most of its own reactors.
The milestone list runs back further than the listing does. Aarti Organic Private Limited was incorporated in 1984. The first API unit at Dombivli and the Xanthine unit both started in 2001; Tarapur Unit 4 followed in 2005 for regulated markets, and cleared USFDA and EU GMP audits in 2008. Caffeine production began at Unit 5 in 2016 at 100 metric tons a month. Land at Atali was acquired in 2022, Phase 1 there commissioned in 2025 with 450+ kL of reactor capacity, and in June 2026 Tarapur Unit 5 was inaugurated with 3,600 TPA of added Xanthine capacity, taking the total to 9,600 TPA.
The company is part of the Aarti group, described in the August 2026 presentation as a diversified chemical conglomerate with FY26 group turnover above ₹145 billion. Aarti Pharmalabs itself runs seven manufacturing units across Maharashtra and Gujarat, three of them USFDA-approved, plus three R&D centres and 2,400+ employees.
Recent months brought a steady stream of filings: a Form 483 with one procedural observation after a USFDA inspection at Tarapur Unit-IV in March 2026; a dimethyl sulphate leak at Tarapur Unit-VI on 22 March 2026, after which the company disclosed that 22 workers were hospitalised, an FIR was filed and operations were restored within 24 hours; and the appointment of Dr. Rakeshwar Bandichhor as Chief Scientific Officer – R&D from 1 January 2026. Crisil's March 2026 credit bulletin lists nine bank facilities, all rated Crisil AA-/Stable.
Business model
Three businesses share one factory network, and only one of them is famous.
**Xanthine derivatives** is the caffeine business, and Aarti has India's largest capacity in it — plus, per the presentation, the world's third-largest. The portfolio runs Caffeine, Theophylline Anhydrous, Aminophylline, Etophylline and Theophylline, and the end uses are cola drinks, energy drinks, pharmaceuticals and nutraceuticals. In volume terms, 74% of Q1 sales went to beverages and 26% elsewhere. Two dedicated Tarapur plants now carry 9,600+ MTPA, up from 5,000 MTPA, with 79% of Q1 sales exported. Global market share is 15–20%, which means that a meaningful slice of the world's morning is manufactured in coastal Maharashtra and shipped out in drums.
**APIs and Intermediates** is the technically demanding one: HPAPIs for oncology, corticosteroids and cytotoxic medicines, backed by 1,500+ KL of multipurpose reactor capacity and 14 API finished lines. The company lists 61 commercialised APIs, 11 more under development, 60 US DMF approvals, 44 CEP approvals and 140+ intermediates. The therapeutic list — anti-diabetic, cardiovascular, calcimimetic, CNS agent, anti-asthmatic, decongestant, overactive bladder, oncology, analgesic, skin care, anti-cancer, anti-thalassaemic — reads like someone emptied a pharmacy into a spreadsheet and alphabetised the aftermath. Q1 market split: 58% regulated, 28% non-regulated, 14% RoW.
**CDMO/CMO** is the contract business, working with 22 customers on 57 active projects — 37 commercial, 20 in development. Management positions the entry point at "Phase II, Phase III changeover and then the commercialization," rather than early discovery. Capabilities on offer include cyanation, flow chemistry, cryogenic reactors from -100°C to +150°C, and hydrogenation from 0.1 to 10 KL — a menu written for chemists, by chemists, with no concession whatsoever to the general reader.
Clients number 500+ globally, including Liconsa Laboratories and Caribbean Refrescos abroad and Dr. Reddy's, Zydus Healthcare and Glenmark at home. Exports go to 50+ countries. R&D employs 122 process scientists including 25+ PhDs, and FY26 R&D spend was ₹65 crore, or 7.4% of API, Intermediates and CDMO sales.
Quarterly results, balance sheet, cash flow, ratios, shareholding and the filings themselves are on the full page for Aarti Pharmalabs Limited.
Companies in the same industry as Aarti Pharmalabs Limited
Pharmaceuticals